1. Risk factors for the development of aneurysmal subarachnoid hemorrhage (SAH) include all of the following, EXCEPT:
A. Hypertension
B. Male gender
C. Smoking
D. Genetic/familial factors
E. Stimulant use
2. All of the following are characteristic signs and symptoms of SAH, EXCEPT:
A. Headache
B. Neck stiffness
C. Photophobia
D. Bilateral weakness
E. Seizure
3. Immediate treatment and stabilization of patients with aneurysmal SAH prior to surgical intervention should include which of the following:
A. Reduction of the mean arterial pressure no greater than 25% less than the mean arterial pressure at admission
B. Nimodipine 60 mg by mouth (PO), every 4 hours (q4h) for 21 days
C. Fluid resuscitation to a central venous pressure of 8 to 12 mm Hg
D. Reduction of the systolic blood pressure to less than 140 mm Hg
E. Tranexamic acid 1 gm intravenously
4. All of the following are common medical complications associated with aneurysmal SAH, EXCEPT:
A. Hyponatremia
B. Fever
C. QTc prolongation
D. Hydrocephalus
E. Acute renal failure
5. Which of the following would be an appropriate treatment consideration for a patient with cerebral vasospasm:
A. Fluid boluses to maintain hypervolemia
B. Inotropic agent to ensure adequate cerebral perfusion
C. Increase the nimodipine dose to 60 mg every 2 hours
D. Antiepileptic drugs
E. None of the above
6. Which of the following agents has consistently shown benefit in large, randomized clinical trials for the treatment of patients with aneurysmal SAH:
A. Nimodipine
B. Albumin
C. Simvastatin
D. Magnesium
E. Clazosentan
7. Which of the following is the standard dose of nimodipine for a patient with aneurysmal SAH:
A. 60 mg q4h for 21 days
B. 30 mg q4h for 21 days
C. 60 mg q4h until vasospasm subsides
D. 30 mg q2h for 21 days
E. None of the above
8. Bedside extraction of nimodipine is associated with which of the following:
A. Increased accuracy of dosing
B. Increased nursing satisfaction
C. Inadvertent intravenous administration
D. More rapid administration
E. None of the above
9. Which of the following is the most appropriate method of bedside nimodipine solution extraction from the capsule:
A. Puncturing with a needle
B. Soaking in water
C. Use of tablet crusher
D. 5 seconds on medium power in microwave
E. None of the above
10. Which of the following is correct regarding the new commercial nimodipine product (Nymalize):
A. It can be administered intravenously
B. It is strawberry flavored
C. It must be pulled into syringes by the pharmacy
D. It is more time efficient than pharmacy-initiated nimodipine extraction
E. None of the above
Evaluation Questions
11. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. To what extent did the program meet objective #3?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. To what extent did the program meet objective #4?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. To what extent did the program meet objective #5?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
19. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
20. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
21. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
22. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
23. Will the information presented cause you to change your practice?
A. Yes
B. No
24. Are you committed to making these changes?
A. Yes
B. No
25. As a result of this activity, did you learn something new?
A. Yes
B. No
26. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
27. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20
